10-QHealthcare

Outlook Therapeutics, Inc.

OTLK · Period ending 2026-06-30 · Filed 2026-08-18 · Updated

In short

Outlook Therapeutics, Inc. (OTLK) has net income up 17.2% to -$62.4M and EPS (Diluted) up 55.9% to $-1.79 year on year. Its gross margin 4.0%. Fisclear flags 4 high-severity risks, led by: Net loss of $62.4M — the company spent more than it earned. Investors should monitor the path to profitability. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$0.39

Beta

0.71

Moderate market correlation

52-Week Range

$0.16$0.39 now$2.54

Decision Context

Altman Z-Score indicates financial distress risk. Review debt levels and cash runway before any position sizing decision.

Based on filing period ending Jun 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

OTLK vs

Macro Context

Fed Funds Rate

3.75%

Accommodative

10-Year Treasury

4.99%

2026-09-01

Unemployment

4.2%

Near full employment

CPI Index

334.1

2026-08-01

M2 Money Supply

$23.3T

2026-08-01

The Federal Funds rate stands at 3.75% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.99%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 103.1; M2 money supply is $23.3T; CPI index stands at 334.1.

SWOT Analysis — OTLK

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • EPS (Diluted): $-1.79 (+55.9% YoY) — Negative EPS — the company recorded a loss on a per-share basis.

  • Operating Cash Flow: -$51.8M (+24.7% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.

  • Net Income: -$62.4M (+17.2% YoY) — The company posted a net loss — total expenses exceeded total revenue.

◈

Weaknesses

  • Total Assets: $18.6M (-35.5% YoY) — Total assets shrank 36% — the balance sheet contracted.

  • R&D spending is 1923% of revenue — heavy investment in future growth, but also a drag on current profitability.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

  • Net loss of $62.4M — the company spent more than it earned. Investors should monitor the path to profitability.

  • Negative operating cash flow of $51.8M — the core business consumed more cash than it generated.

  • Total liabilities are 273% of total assets — the balance sheet is heavily leveraged with limited equity cushion.

  • Current ratio of 0.38x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.

Quarter-over-Quarter Comparison

2026-03-31 → 2026-06-30
Metric2026-03-312026-06-30Change
Revenue$8M$1M
▼82.6%
Gross Profit57205.0057205.00
–0.0%
Operating Income$-67M$-67M
–0.0%
Net Income$-62M$-62M
–0.0%
EPS (diluted)$-1.79$-1.79
–0.0%
Operating CF$-52M$-52M
–0.0%

Risk factor changes vs prior filing

NEW

R&D spending is 1923% of revenue — heavy investment in future growth, but also a drag on current profitability.

REMOVED

R&D spending is 334% of revenue — heavy investment in future growth, but also a drag on current profitability.

Year-over-Year Changes

EPS (Diluted)

$-1.79

was $-4.06

+55.9%

Negative EPS — the company recorded a loss on a per-share basis.

Total Assets

$18.6M

was $28.8M

−35.5%

Total assets shrank 36% — the balance sheet contracted.

Operating Cash Flow

-$51.8M

was -$68.8M

+24.7%

Negative operating cash flow — the business consumed more cash than it produced from operations.

Net Income

-$62.4M

was -$75.4M

+17.2%

The company posted a net loss — total expenses exceeded total revenue.

Risk Flags

4 high · 0 medium · 1 low
  • ⚠ High

    Net loss of $62.4M — the company spent more than it earned. Investors should monitor the path to profitability.

  • ⚠ High

    Negative operating cash flow of $51.8M — the core business consumed more cash than it generated.

  • ⚠ High

    Total liabilities are 273% of total assets — the balance sheet is heavily leveraged with limited equity cushion.

  • ⚠ High

    Current ratio of 0.38x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.

  • ○ Low

    R&D spending is 1923% of revenue — heavy investment in future growth, but also a drag on current profitability.

Technical Signals

Daily closes · 1-year data

Outlook Therapeutics, Inc.: common questions

Is Outlook Therapeutics, Inc. profitable?

No. Outlook Therapeutics, Inc. reported a net loss of $62M in its latest fiscal year (fiscal 2025).

What is Outlook Therapeutics, Inc.'s P/E ratio?

Outlook Therapeutics, Inc. has no meaningful P/E ratio at the moment, because it lost money over the latest year. P/E only works when earnings are positive.

Does Outlook Therapeutics, Inc. pay a dividend?

No dividend is currently expected from Outlook Therapeutics, Inc., according to the latest market data.

What are the main risks for Outlook Therapeutics, Inc.?

Fisclear's checks flag 4 medium- or high-severity risks. The most serious: Net loss of $62.4M — the company spent more than it earned. Investors should monitor the path to profitability.

Answers are generated from the figures in this report (updated 9 Oct 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — OTLK

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade OTLK

Links open broker research pages. Not an endorsement or recommendation.

Research Outlook Therapeutics, Inc.

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.